DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Rad Oncology Homepage

Elekta Unity MR-linac gains FDA 510(k) clearance Simultaneously delivers radiation dose and visualization of tumors

Dr. Hermann Requardt United Imaging Healthcare appoints senior scientific advisor

Patient denied proton therapy dies, family received $25 million in court Points to the need for greater treatment coverage for certain cancer patients

Microbeam radiation therapy could lead to single session treatments Healthy cells tolerate treatment while tumors lose structure

CMS to unveil mandatory payment model for radiation oncology Part of determining approach that saves more and offers greater quality

European report says radiotherapy 'undervalued' and needing 'greater investment' Equipment shortages, lack of investment, training variations

ViewRay to supply UK's GenesisCare with country's first MRIdian systems Providing soft-tissue imaging in real time and better tumor targeting

Accuray showcases software upgrades for CyberKnife and Radixact at ASTRO Allows for 40 percent faster treatment delivery

Precision cancer care with proton and radiation oncology Some of the latest systems and software entering the market

IBA Dosimetry debuts myQA Daily at ASTRO 2018 Has 125 ionization chamber measurement points

International brain cancer consortium takes aim at better linear accelerator outcomes

by John W. Mitchell , Senior Correspondent
A just-announced initiative between Elekta and physicians at health care systems in three countries will work to set best practice standards for treating brain cancer patients with noninvasive stereotactic radiosurgery (SRS) and stereotactic radiation therapy (SRT) using linear accelerators.

“The inaugural meetings held recently were to identify SRS clinical practices at consortia members in the U.S., Canada and Germany,” Kris Walmsley, corporate communications manager at Elekta told HCB News. “These members treat high patient volumes and offer influential academic radiotherapy institutions.

Story Continues Below Advertisement

RamSoft PowerServer™ RIS/PACS - Enabling Efficient Diagnostic Imaging

RamSoft's PowerServer™ RIS/PACS is an intuitive, single database application that enables healthcare practices to operate diagnostic imaging more efficiently than ever before.Why is this important? Click to find out.



The three founding members are: Massachusetts General Hospital; Odette Cancer Center at Sunnybrook Health Sciences Centre, University of Toronto, Canada; and University Medical Center, Mannheim Germany.

SRS and SRT are noninvasive focused radiation treatments for brain disorders, including cancer. About 70,000 patients worldwide receive the therapy annually. The treatment delivers pinpoint, high doses of radiation through the skull. The consortium’s goal, according to Dr. Joel Goldwein, Elekta’s senior vice president of Medical Affairs, is to improve clinical confidence and outcomes and lead to greater implementation of the procedure.

According to a 1996 study published in Cancer, between 25-45 percent of oncology patients’ cancer spreads to the brain.

“This is an exciting international collaborative,” said Dr. Arjun Sahgal, associate professor of radiation oncology and surgery, University of Toronto. He said the group will initially study the differences between single treatments and hypofractionated treatments (delivered in multiple doses) as to how both methods relate to minimizing the impact of the radiation and effectiveness in obliterating the tumor.

“We have the ability to report on our outcomes and toxicities with both approaches and for intact tumors, surgical cavities and benign tumors,” said Sahgal

Sahgal said SRS and SRT are emerging techniques. The group plans to work to help the physician community develop new, safe treatments for applying brain stereotactic technology. Goldwein said that the group first plans to conduct a medical practice survey on intact brain metastases and a tumor contouring study. Once the results are published, a retrospective observational study is planned to examine correlations with clinical outcomes.

“We want the consortium to identify any clinical evidence gaps to help derive consensus guidelines on linac-based brain stereotactic procedures.” Goldwein added. He said that eliminating variability in current treatments would help validate best practices and also enhance efficacy and safety.

“Our ultimate goals is to improve outcomes for these unfortunate prognosis patients,” he said.

According to Walmsley, Elekta will fund the consortium’s research.

Rad Oncology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED